Search

Your search keyword '"Hôpital Jeanne de Flandres"' showing total 3 results
Start Over Author "Hôpital Jeanne de Flandres" Journal british journal of haematology
3 results on '"Hôpital Jeanne de Flandres"'

1. Results of successive EORTC‐CLG 58 881 and 58 951 trials in paediatric T‐cell acute lymphoblastic leukaemia (ALL)

Author

Yves Bertrand, Dominique Plantaz, Catherine Paillard, Mattias Hofmans, Odile Minckes, Pieter Van Vlierberghe, Hélène Cavé, Geneviève Plat, Alina Ferster, Vitor Costa, Karima Yakouben, Anne Uyttebroeck, Jutte van der Werff ten Bosch, Sandrine Girard, Pauline Simon, Barbara De Moerloose, Frédéric Millot, Stefan Suciu, Pierre Rohrlich, Caroline Piette, Marilyne Poirée, Françoise Mazingue, Nicolas Sirvent, European Organisation for Research and Treatment of Cancer [Bruxelles] (EORTC), European Cancer Organisation [Bruxelles] (ECCO), Center for Medical Genetics [Ghent], Ghent University Hospital, Hôpital Jeanne de Flandres, Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Université de Montpellier (UM), CHU Strasbourg, University Hospitals Leuven [Leuven], Département de pédiatrie, CHU Grenoble-Hôpital Michallon, CHU Toulouse [Toulouse], CHU Pointe-à-Pitre/Abymes [Guadeloupe], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Centre hospitalier universitaire de Poitiers (CHU Poitiers), Hopital L'Archet-II, Centre Hospitalier Universitaire de Liège (CHU-Liège), CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), CIC CHU Lyon (inserm), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Lyon, Clinical sciences, Growth and Development, and Pediatrics

Subjects
Male, T-cell acute lymphoblastic leukaemia, medicine.medical_specialty, Asparaginase, Adolescent, [SDV]Life Sciences [q-bio], medicine.medical_treatment, cranial radiotherapy, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Gastroenterology, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, childhood leukaemia, White blood cell, Internal medicine, medicine, Humans, Child, Dexamethasone, Medicine(all), Clinical Trials as Topic, Chemotherapy, Hematology, business.industry, Hazard ratio, Infant, Newborn, Infant, Induction chemotherapy, asparaginase, Survival Analysis, 3. Good health, EORTC, Treatment Outcome, medicine.anatomical_structure, chemistry, Child, Preschool, 030220 oncology & carcinogenesis, Prednisolone, Childhood Leukaemia, Female, business, Hématologie, 030215 immunology, medicine.drug
Abstract

Outcomes in childhood T-cell acute lymphoblastic leukaemia (T-ALL) are steadily improving due to intensive therapy. Between 1989 and 2008, 599 children with newly diagnosed T-ALL were enrolled in two successive European Organization for Research and Treatment of Cancer - Children's Leukaemia Group trials (58881 and 58951), both based on the Berlin-Frankfurt-Munster protocol and without cranial irradiation. In the latter trial induction chemotherapy was intensified. The most important randomizations were Medac Escherichia coli asparaginase versus Erwinia asparaginase in trial 58881, and dexamethasone (6 mg/m2/day) versus prednisolone (60 mg/m2/day) and prolonged versus conventional asparaginase duration in trial 58951. 8-year event-free survival (EFS) increased from 65·1% to 74·0% in trial 58951. Improvement was most profound for patients with white blood cell (WBC) counts, SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2019
Full Text
View/download PDF

2. Incidence and risk factors for clinical neurodegenerative Langerhans cell histiocytosis: a longitudinal cohort study

Author

Nathalie Aladjidi, Jean-François Emile, Frédéric Millot, Kamila Kebaili, Laurence Brugières, Valérie Taly, Anne Lutun, Catherine Paillard, Mohamed-Aziz Barkaoui, Julien Haroche, Zofia Hélias-Rodzewicz, Claire Galambrun, Fleur Cohen-Aubart, Hélène Pacquement, Jean Miron, Guy Leverger, Eric Jeziorski, Françoise Mazingue, Anne Pagnier, Marion Gillibert-Yvert, Anne Deville, Jean-Louis Stephan, Anne Lambilliotte, Nadine Martin-Duverneuil, Isabelle Pellier, Ahmed Idbaih, Geneviève Plat, Virginie Gandemer, Sébastien Héritier, Caroline Thomas, Jean Donadieu, Khê Hoang-Xuan, Despina Moshous, Ludovic Mansuy, Sorbonne Université - Faculté de Médecine (SU FM), Sorbonne Université (SU), Hôpital Trousseau, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hôpital mère et enfant, Developpement Normal et Pathologique du Système Immunitaire, Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service d'hématologie pédiatrique-oncologie, Hôpital Jeanne de Flandre [Lille]-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Hôpital Jeanne de Flandres, Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Institut d’Hémato-Oncologie Pédiatrique, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), CHU Toulouse [Toulouse], Service d'Hémato-oncologie Pédiatrique, CHU Bordeaux [Bordeaux]-Hôpital Pellegrin, Institut Curie [Paris], Service d'Hématologie pédiatrique, Hôpital de la Timone, Marseille, Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Département de cancérologie de l'enfant et de l'adolescent [Gustave Roussy], Institut Gustave Roussy (IGR), Service d'hématologie-immunologie-oncologie pédiatrique [CHU Trousseau], Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Service d'Hématologie et d'Oncologie Pédiatrique [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Université Pierre et Marie Curie - Paris 6 - UFR de Médecine Pierre et Marie Curie (UPMC), Université Pierre et Marie Curie - Paris 6 (UPMC), Centre Hospitalier Universitaire de Nice (CHU Nice), Service Immuno Hémato-Onco Pédiatrique, CHU Grenoble, CHU Amiens-Picardie, CHU Trousseau [Tours], Service d'hématologie pédiatrique, CHU Saint-Etienne, Centre National de Référence du Lupus Systémique, Syndrome des Anticorps Anti-phospholipides et Maladies Auto-immunes Systémiques Rares [CHU Pitié Salpêtrière], Service de Médecine Interne 2, maladies auto-immunes et systémiques [CHU Pitié-Salpêtrière], Institut E3M [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Institut E3M [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre de Recherche en Cancérologie Nantes-Angers (CRCNA), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM)-Hôtel-Dieu de Nantes-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Laennec-Centre National de la Recherche Scientifique (CNRS)-Faculté de Médecine d'Angers-Centre hospitalier universitaire de Nantes (CHU Nantes), Hôpital Jean Bernard, Service de médecine de l'enfant et de l'adolescent, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière (CRICM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Médecine Personnalisée, Pharmacogénomique, Optimisation Thérapeutique (MEPPOT - U1147), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Equipe labellisée Ligue contre le Cancer, Biomarqueurs et essais cliniques en Cancérologie et Onco-Hématologie (BECCOH), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Saclay, Biologie des Interactions Neurones / Glie, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Sorbonne Université - Département de neurologie 2 - Mazarin, Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Molecular analysis of LCH samples was supported by a grant (#11413) from the Conquer Cancer Foundation ASCO Young Investigator Award, supported by the Strike 3 Foundation. This study received grants from the Société Française de lutte contre les Cancers de l’Enfant et de l’Adolescent, Fédération Enfants et Santé, Association Recherche et Maladie Hématologiques de l’Enfant, Association Les 111 des Arts de Paris, Association la Petite Maison dans la Prairie. This project received constant support from the Association Histiocytose France. The French LCH registry was supported by a grant from InVS and INSERM for the rare disease registry, a grant from Roche and from the Gardrat Family. This study was based on research from the Centre de Reference des Histiocytoses (www.histiocytose.org)., Service d'Onco-neurologie = Département de neurologie 2 [CHU Pitié Salpêtrière], TALY, Valerie, Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Service de médecine de l'enfant et de l'adolescent [CHU Rennes], and CHU Pontchaillou [Rennes]

Subjects
Male, Pituitary gland, Pediatrics, medicine.medical_specialty, Adolescent, [SDV]Life Sciences [q-bio], [SDV.CAN]Life Sciences [q-bio]/Cancer, Disease, BRAF, 03 medical and health sciences, 0302 clinical medicine, [SDV.CAN] Life Sciences [q-bio]/Cancer, Langerhans cell histiocytosis, Risk Factors, [SDV.BBM] Life Sciences [q-bio]/Biochemistry, Molecular Biology, Medicine, Humans, [SDV.BBM]Life Sciences [q-bio]/Biochemistry, Molecular Biology, Cumulative incidence, Longitudinal Studies, Registries, Longitudinal cohort, Child, business.industry, Incidence (epidemiology), Incidence, neurodegeneration, Infant, Newborn, Infant, Neurodegenerative Diseases, Hematology, medicine.disease, 3. Good health, [SDV] Life Sciences [q-bio], Histiocytosis, Langerhans-Cell, medicine.anatomical_structure, Bone lesion, 030220 oncology & carcinogenesis, Child, Preschool, Female, histiocytosis, business, Previously treated, 030215 immunology, Follow-Up Studies
Abstract

International audience; Neurodegenerative (ND) complications in Langerhans cell histiocytosis (LCH) are a late-onset but dramatic sequelae for which incidence and risk factors are not well defined. Based on a national prospective registry of paediatric LCH patients, we determined the incidence rate of clinical ND LCH (cND-LCH) and analysed risk factors, taking into account disease extent and molecular characteristics. Among 1897 LCH patients, 36 (1·9%) were diagnosed with a cND-LCH. The 10-year cumulative incidence of cND-LCH was 4·1%. cND-LCH typically affected patients previously treated for a multisystem, risk organ-negative LCH, represented in 69·4% of cND-LCH cases. Pituitary gland, skin and base skull/orbit bone lesions were more frequent (P < 0·001) in cND-LCH patients compared to those without cND-LCH (respectively 86·1% vs. 12·2%, 75·0% vs. 34·2%, and 63·9% vs. 28·4%). The 'cND susceptible patients' (n = 671) i.e., children who had experienced LCH disease with pituitary or skull base or orbit bone involvement, had a 10-year cND risk of 7·8% vs. 0% for patients who did not meet these criteria. Finally, BRAFV 600E status added important information among these cND susceptible patients, with the 10-year cND risk of 33·1% if a BRAFV 600E mutation was present compared to 2·9% if it was absent (P = 0·002).

Published
2018
Full Text
View/download PDF

3. Lethal ALAS2 mutation in males X-linked sideroblastic anaemia.

Author

Rose C, Callebaut I, Pascal L, Oudin C, Fournier M, Gouya L, Lambilliotte A, and Kannengiesser C

Subjects
5-Aminolevulinate Synthetase chemistry, Amino Acid Sequence, Anemia, Sideroblastic diagnosis, Bone Marrow pathology, DNA Mutational Analysis, Erythrocyte Indices, Female, Genetic Diseases, X-Linked diagnosis, Germ-Line Mutation, Heterozygote, Humans, Male, Models, Molecular, Pedigree, Phenotype, Protein Conformation, 5-Aminolevulinate Synthetase genetics, Anemia, Sideroblastic genetics, Genes, Lethal, Genetic Diseases, X-Linked genetics, Mutation
Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results